Santen Pharmaceutical Co (STU:SZD) Accounts Payable: €147 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:SZD Santen Pharmaceutical Co Ltd STU:SZD
89 GF Score
Price €10.00
GF Value €9.17
Valuation Fairly Valued
View Full Analysis

What is Santen Pharmaceutical Co Accounts Payable?

Santen Pharmaceutical Co STU:SZD -2.91% 89 Accounts Payable is €147 Mil as of Jun. 2026. GuruFocus rates STU:SZD with a GF Score™ of 89/100 and a GF Value™ of €9.17 (Fairly Valued).

Santen Pharmaceutical Co's Accounts Payable for the quarter that ended in Jun. 2026 was €147 Mil.

Santen Pharmaceutical Co's quarterly Accounts Payable increased from Dec. 2025 (€180 Mil) to Mar. 2026 (€193 Mil) but then declined from Mar. 2026 (€193 Mil) to Jun. 2026 (€147 Mil).

Santen Pharmaceutical Co's annual Accounts Payable declined from Mar. 2024 (€267 Mil) to Mar. 2025 (€242 Mil) and declined from Mar. 2025 (€242 Mil) to Mar. 2026 (€193 Mil).

Santen Pharmaceutical Co Accounts Payable Related Terms

Santen Pharmaceutical Co Accounts Payable Historical Data

* Premium members only.

The historical data trend for Santen Pharmaceutical Co's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Santen Pharmaceutical Co Accounts Payable Chart

Santen Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 315.37 314.06 267.31 241.95 192.70

Santen Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 254.20 176.39 179.95 192.70 146.77
STU:SZD
89GF Score
Santen Pharmaceutical Co Ltd STU:SZD
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Santen Pharmaceutical Co Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of €147 Mil mean?
Santen Pharmaceutical Co (STU:SZD) has a Accounts Payable of €147 Mil as of Jun. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Santen Pharmaceutical Co and its competitors.
Is Santen Pharmaceutical Co's Accounts Payable too high?
Santen Pharmaceutical Co's current Accounts Payable is €147 Mil. Overall, Santen Pharmaceutical Co has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Santen Pharmaceutical Co's Accounts Payable compare to LLY and JNJ?
Santen Pharmaceutical Co's Accounts Payable of €147 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Drug Manufacturers company?
A good Accounts Payable depends on the Drug Manufacturers industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Santen Pharmaceutical Co and its competitors. Santen Pharmaceutical Co's current Accounts Payable is €147 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Santen Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Santen Pharmaceutical Co (STU:SZD) is currently considered Fairly Valued. The stock's GF Value™ is €9.17, compared to a current price of €10.00 — trading 9.1% above its estimated fair value. The current Accounts Payable is €147 Mil. Santen Pharmaceutical Co's overall GF Score™ is 89/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Santen Pharmaceutical Co (STU:SZD), the current Accounts Payable is €147 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Santen Pharmaceutical Co (STU:SZD) Overvalued in 2026?

Based on GuruFocus' analysis, Santen Pharmaceutical Co stock appears to be overvalued. The current stock price of €10.00 is trading 9.1% above its estimated GF Value™ of €9.17. GuruFocus considers Santen Pharmaceutical Co to be Fairly Valued.

Key valuation signals for STU:SZD:

  • Accounts Payable: €147 Mil
  • GF Value™: €9.17 vs. price of €10.00 (9.1% above fair value)
  • GF Score™: 89/100

No single metric tells the full story. See the STU:SZD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Santen Pharmaceutical Co Business Description

Other Exchanges SNPHY:USA4536:Japan
Address 4-20 Ofukacho, Grand Front Osaka Tower A, Kita-ku, Osaka Prefecture, Osaka, JPN, 530-8552
Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company provides a wide range of prescription and over-the-counter eye care products, including treatments for glaucoma, dry eye, and allergies. It also develops surgical and diagnostic devices related to eye care.
89GF Score

Get the complete analysis for STU:SZD

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€10.00
Price
€9.17
GF Value